Dashboard
Manage Tickers

ABUS


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

chardan-capital-maintains-buy-on-arbutus-biopharma-maintains-5-price-target
Chardan Capital Maintains Buy on Arbutus B...
08/11/2025 11:22:09

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

arbutus-biopharma-q2-eps-001-beats-005-estimate-sales-1074m-beat-159m-estimate
Arbutus Biopharma Q2 EPS $0.01 Beats $(0.0...
08/06/2025 11:40:28

arbutus-reacquires-greater-china-rights-to-imdusiran-from-qilu-forms-scientific-advisory-board-focused-on-late-stage-hepatitis-b-trials
Arbutus Reacquires Greater China Rights To...
06/25/2025 11:33:14

arbutus-biopharma-q1-eps-013-misses-010-estimate-sales-176m-miss-178m-estimate
Arbutus Biopharma Q1 EPS $(0.13) Misses $(...
05/14/2025 11:36:28

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $...

arbutuss-imdusiran-plus-vtp-300-and-low-dose-nivolumab-achieve-hbsag-loss-and-seroconversion-in-chbv-patients-new-phase-2a-data-reveal-at-easl-2025
Arbutus's Imdusiran Plus VTP-300 And Low-D...
05/07/2025 07:10:36

Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV...

arbutus-biopharma-to-present-key-hepatitis-b-data-including-late-breaker-at-easl-congress-2025
Arbutus Biopharma To Present Key Hepatitis...
04/23/2025 06:29:12

chardan-capital-maintains-buy-on-arbutus-biopharma-maintains-5-price-target
Chardan Capital Maintains Buy on Arbutus B...
03/28/2025 12:39:04

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

arbutus-biopharma-fy-2024-gaap-eps-038-up-from-044-yoy-sales-617m-down-from-1814m-yoy
Arbutus Biopharma FY 2024 GAAP EPS $(0.38)...
03/27/2025 11:43:17

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.38) per share. This is a 13.64 percent increase over losses of...

Core News & Articles
Roviant Sciences Subsidiary, Genevant Scie...
03/03/2025 14:16:36

arbutus-biopharma-appoints-lindsay-androski-as-ceo-amid-major-board-reshuffle
Arbutus Biopharma Appoints Lindsay Androsk...
02/25/2025 12:47:59

In addition to Ms. Androski, four new directors have joined the board: Robert Alan Beardsley, Joseph Bishop, Matthew Gline and ...

hc-wainwright--co-reiterates-buy-on-arbutus-biopharma-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Arbu...
01/21/2025 13:07:39

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

arbutus-biopharma-held-123m-in-cash-balance-eying-placebo-controlled-phase-2b-clinical-trial
Arbutus Biopharma Held $123M In Cash Balan...
01/13/2025 12:46:44

Imdusiran (RNAi therapeutic)At the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® in Novembe...

whitefort-capital-sends-letter-to-arbutus-biopharma-board-of-directors-believes-now-is-the-time-for-arbutus-to-pursue-a-license-and-collaboration-agreement-with-a-strategic-partner-and-explore-all-options-for-hbv-portfolio
Whitefort Capital Sends Letter To Arbutus ...
12/03/2024 13:24:00

Believes Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explo...

walmart-to-rally-more-than-15-here-are-10-top-analyst-forecasts-for-wednesday
Walmart To Rally More Than 15%? Here Are 1...
11/20/2024 12:45:06

chardan-capital-maintains-buy-on-arbutus-biopharma-raises-price-target-to-5
Chardan Capital Maintains Buy on Arbutus B...
11/20/2024 10:58:45

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $4....

hc-wainwright--co-reiterates-buy-on-arbutus-biopharma-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Arbu...
11/18/2024 12:17:37

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Core News & Articles
Arbutus And Barinthus Bio Report IM-PROVE ...
11/15/2024 16:02:56

hc-wainwright--co-reiterates-buy-on-arbutus-biopharma-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Arbu...
11/07/2024 13:05:54

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

chardan-capital-maintains-buy-on-arbutus-biopharma-raises-price-target-to-45
Chardan Capital Maintains Buy on Arbutus B...
11/07/2024 00:21:10

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $4 ...

as-of-september-30-2024-arbutus-had-cash-cash-equivalents-and-investments-in-marketable-securities-of-1308m-expected-to-provide-cash-runway-into-q4-of-2026
As Of September 30, 2024, Arbutus Had Cash...
11/06/2024 12:43:07

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION